Adalimumab biosimilar (Sinocelltech)

阿达木单抗生物类似药（神州细胞工程）

Report date: 2023/06/13 15:55:24

Base Information

Drug NameAdalimumab biosimilar (Sinocelltech)
Drug Alias Name重组抗肿瘤坏死因子-α全人源单抗 （神州细胞工程）阿达木单抗生物仿制药（神州细胞工程）重组抗TNFa全人单抗（神州细胞工程）安佳润SCT-630
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Global Approved IndicationsPsoriasisUveitisCrohn Disease +[7] 
Approved Indications in ChinaPsoriasisUveitisCrohn Disease +[7] 
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/07
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinoCelltech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinocelltech Group LtdSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A